Why the study?
Does bivalirudin reduce ischemic and bleeding complications as an alternative to heparin in patients undergoing interventional procedures?
Does bivalirudin reduce ischemic and bleeding complications as an alternative to heparin in patients undergoing interventional procedures?
Bivalirudin is a direct thrombin inhibitor that serves as an effective alternative to heparin for reducing ischemic and bleeding complications during percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
May inform bivalirudin use in PCI; leaves open need for updated randomized trials.
Summary Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.
No takes yet. Share an insight, caveat, or question.
Derek P. Chew (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: